Quarterly Report reflects both 79% year-to-year increase and 50% over the second quarter of 2014; Covington and Burling tops global legal advisors leading deals
DECEMBER 4, 2014 – BOSTON, MA -- BioPharm Insight, the life sciences industry’s premier source for breaking news and forward-looking analysis of drug developments and forecasting data, today released its 3Q14 Licensing League Table – which ranks legal advisors for global biotech and pharmaceutical licensing deals. The quarterly rankings report reflects both the value and volume of the deals and provides key insight into pivotal market opportunities and prevailing trends impacting the entire sector.
“We’ve seen dramatic increases in the value of licensing activity in the third quarter of this year, compared to both the previous quarter and the same quarter last year,” said BioPharm Insight Editor-in-Chief Querida Anderson. “This robust expansion throughout the sector – and all the key participants making it happen -- reflects the kind of indispensable information BioPharm Insight makes exclusively available to its readers.”
The total volume and disclosed value of licensing agreements involving pharmaceutical products picked up significantly in 3Q14. The quarter has seen 125 agreements with an aggregate disclosed value of $11.3 billion, an increase of approximately 50% in value and 24% in volume over 2Q14. The licensing agreement between Almirall and AstraZeneca (NASDAQ: AZN), involving the respiratory franchise, was the largest deal for the quarter, potentially valued at $2.1 billion. By comparison, during 3Q13, just 120 licensing agreements at an aggregate disclosed value of $6.3 billion were completed globally.
Among law firms leading licensing deals in North America, Covington and Burling led in value, having advised on 17 transactions valued at $5.4 billion. Globally, Covington and Burling also ranked first in the value table for trailing twelve months ending in the third quarter of 2014, having advised on 20 drug licensing agreements valued at more than $6.5 billion.
Goodwin Proctor led the global and North American volume tables for trailing twelve months ending third quarter 2014, with 26 transactions valued at $2.7 billion.
To read the full BioPharm Insight 3Q14 League Table, please fill out the form above.
About BioPharm Insight’s League Licensing Table
Biotech and pharma licensing trends are based on all agreements, irrespective of deal value and geography, that are classified as pharmaceutical drug licensing agreements and drug/portfolio of drug acquisition deals between pharma/biotech companies, universities/research institutes. Transactions excluded from the tables are: M&A deals, fundraising activities, service agreements, manufacturing/supply agreements, and licensing of technology, medical devices and diagnostic tests. Preliminary agreements such as letters of intent and memorandums of understanding have been excluded; option agreements are included only when there is evidence of financial commitment (e.g. upfront payment, R&D funding) on the part of the licensee.
About Infinata’s BioPharm Insight
BioPharm Insight is Infinata’s flagship intelligence solution for the global healthcare markets. With its dedicated team of more than a dozen investigative journalists, BioPharm Insight delivers forward-looking, proprietary intelligence to its subscribers every day. BioPharm Insight’s editorial team covers life sciences from offices in New York and London. Featuring a comprehensive BioPharm Solutions Suite, Infinata provides personalized technology solutions to turn information into insight. Infinata is a part of the Mergermarket Group.